首页> 外文OA文献 >Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials

【2h】

Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials

机译：HBV或HCV阳性肝细胞癌患者的索拉非尼和雷罗妥韦：资源和急剧试验分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Andrea Casadei Gardini; Giovanni Luca Frassineti; Francesco Giuseppe Foschi; Giorgio Ercolani; Paola Ulivi;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials [J] . Gardini Andrea Casadei, Frassineti Giovanni Luca, Foschi Francesco Giuseppe, Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver . 2017,第8期

机译：HBV-或HCV阳性肝细胞癌患者中的索拉非尼和雷罗妥苯胺：资源和急剧试验分析
2. 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment [J] . Guohong Han, Philippe Merle, Alessandro Granito, Journal of vascular and interventional radiology: JVIR . 2018,第4Suppla期

机译：下午4:12摘要第379号更新的全身生存（OS）分析来自国际，第3阶段，随机，安慰剂控制的Regorafenib的肝细胞癌治疗患者的肝细胞癌的分析
3. Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment [J] . Merle Philippe, Granito Alessandro, Huang Yi-Hsiang, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：治疗急性的不良事件（茶叶）在索拉非群治疗肝癌治疗患者的随机，受控第3阶段患者的随机治疗阶段3分类试验
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Comparative analysis of epigenetic and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. [D] . Formeister, Eric John. 2010

机译：HCV阳性肝细胞癌患者肿瘤组织和非肿瘤组织表观遗传和基因表达终点的比较分析。
6. Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients [O] . Jordi Bruix 2016

机译：瑞戈非尼和RESORCE试验：肝细胞癌患者的新二线选择
7. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [O] . Bruix, Jordi, Qin, Shukui, Merle, Philippe, 2017

机译：瑞格非尼用于索拉非尼治疗进展的肝细胞癌患者（RESORCE）：一项随机，双盲，安慰剂对照的3期临床试验

Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials

著录项

引文网络

相似文献

相关主题

期刊订阅